Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients

• Published in: Hepatology research Vol. 52; no. 4; pp. 337 - 351
• Main Authors: Luo, Mengqi, Zhou, Bin, Hou, Jinlin, Jiang, Deke
• Format: Journal Article
• Language: English
• Published: Netherlands Wiley Subscription Services, Inc 01.04.2022
• Subjects: Antigens; Biomarkers; chronic; Deoxyribonucleic acid; DNA; Drug withdrawal; Hepatitis B; Hepatitis B e antigen; Hepatitis B surface antigen; Interferon; Patients; predict; Prediction models; Ribonucleic acid; RNA; withdrawal; predict; withdrawal; chronic; Hepatitis B
• ISSN: 1386-6346; 1872-034X
• DOI: 10.1111/hepr.13749

Aim To summarize HBV‐related biomarkers predicting nucleos(t)ide analogs (NAs) discontinuation and hepatitis B virus (HBV) recurrence after drug withdrawal in chronic hepatitis B (CHB) patients, providing references for clinical medication, so as to manage CHB patients more scientifically. Methods Related pieces of literature were retrieved in PubMed and the results were sorted out. We then analyzed and summarized these articles. Results We found that HBV related biomarkers maybe could predict NAs withdrawal safely and the possibility of relapse after treatment cessation, including hepatitis B e antigen (HBeAg), hepatitis B surface antigen (HBsAg), HBV DNA, HBV RNA, pregenomic‐RNA (pgRNA), hepatitis B core‐related antigen (HBcrAg), hepatitis B core antibody (anti‐HBc), and models containing several indicators for predicting the effectiveness of treatment. Conclusions HBV DNA, HBV RNA, pgRNA, HBcrAg, anti‐HBc, as well as the prediction models formed by several biomarkers could predict the safe discontinuation of NAs before HBsAg loss and recurrence.